Official source for corporate press releases, plasma therapeutics production milestones, scientific conferences, and healthcare biotechnology breakthroughs.
A landmark memorandum of understanding for joint biotechnology research and development of specialized immunoglobulin formulations was officially signed.
A landmark memorandum of understanding for joint biotechnology research and development of specialized immunoglobulin formulations was officially signed.
Periodic regulatory and healthcare audits concluded with outstanding scores and zero deviations, affirming Nojin's commitment to world-class aseptic manufacturing.
Presentation of three prominent research papers regarding efficacy optimization of Albojin in intensive care units received accolades from international scientific panels.
Ensuring uncompromising 2°C to 8°C thermal stability from production lines to nationwide clinical centers via real-time GPS telemetry and cloud logging.
Following rigorous biological and technical evaluations, Nojin's advanced human plasma fractionation line was officially inaugurated, marking a transformative leap in biological therapeutics self-sufficiency.
nojin Zist Pharmed's pharmaceutical portfolio is developing new clinical treatment options in line with maximizing the coverage of the country's therapeutic needs.
No news items found in this category.
Committed to supplying biological therapeutics and plasma-derived products with the highest global quality standards.